Online citations, reference lists, and bibliographies.
← Back to Search

Neoadjuvant Chemotherapy Regimens In Treatment Of Breast Cancer: A Systematic Review And Network Meta-analysis Protocol

M. Pathak, S. Dwivedi, S. Deo, B. Thakur, V. Sreenivas, G. Rath
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundNeoadjuvant chemotherapy (NACT), a standard of care for locally advanced breast cancer patients, is widely used for early breast cancer patients also. The varying role of regimens used as NACT needs to be investigated. Despite availability of some randomized controlled trials (RCTs), it is unclear which treatment regimen suits best. Further, there is no study comparing all the three regimens. Accordingly, present study will compare the efficacy of anthracyclines, taxanes, and targeted therapy administered in neoadjuvant setting on the basis of oncological outcomes and functional outcomes.Method/designOnline databases PubMed and Cochrane Register of Controlled Trials will be searched to acquire eligible studies. Further, content of relevant journals, references of relevant articles, and proceedings of major related conference will also be searched. The RCTs comparing any of abovementioned regimen as NACT on breast cancer patients will be eligible. Two reviewers independently and in duplicate will screen the records on the basis of title and abstract and complete full-text review to determine eligibility. Similarly, data extraction and risk of bias assessment will be done by two independent reviewers. The pair-wise meta-analysis as well as network meta-analysis will be conducted to assess the relative efficacy of anthracyclines, taxanes, and targeted therapy regimens.DiscussionThe present systematic review will improve the understanding of the relative efficacies of the three treatment regimens and possibly guide the clinical practices by providing the current best evidence on the efficacy of various regimens of NACT in the management of breast cancer patients.Systematic review registrationPROSPERO (CRD42016027236).
This paper references
10.1177/1536867X1101100206
Multivariate Random-effects Meta-regression: Updates to Mvmeta
I. White (2011)
10.1016/j.breast.2011.06.009
Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.
A. Valachis (2011)
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN
J Ferlay (2012)
10.1200/JCO.2005.06.156
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
T. Evans (2005)
10.1371/journal.pone.0145442
Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials
L. Cao (2015)
10.1016/S1470-2045(11)70094-8
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
H. Bonnefoi (2011)
10.1016/S0140-6736(09)61964-4
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
L. Gianni (2010)
10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
M. K. Parmar (1998)
10.1001/2012.JAMA.11228
How to use an article reporting a multiple treatment comparison meta-analysis.
E. Mills (2012)
10.1200/JCO.2014.57.0572
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
W. Sikov (2015)
10.1002/SIM.1186
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
10.1016/j.jclinepi.2010.03.016
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.
G. Salanti (2011)
10.1056/NEJMoa1111097
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
H. Bear (2012)
10.2174/1570163812666150602144310
Targeted Cancer Therapy: The Next Generation of Cancer Treatment.
T. Baudino (2015)
A revised tool for assessing risk of bias in randomized trials
J. Higgins (2016)
10.1007/s10549-015-3466-4
Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9
J. Abraham (2015)
10.1136/bmj.g7647
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
L. Shamseer (2015)
Comparison of different regimens of neoadjuvant chemotherapy in breast cancer patients: systematic review and network meta-analysis
M Pathak
10.1093/jnci/dju203
Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis.
A. Nagayama (2014)
10.1200/JCO.2005.04.1665
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
H. Bear (2006)
10.1056/NEJMoa1111065
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
G. von Minckwitz (2012)
10.1001/jamaoncol.2015.6113
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
K. Broglio (2016)
10.1002/9780470712184
Cochrane Handbook for Systematic Reviews of Interventions
J. P. Higgins (2019)
Cochrane book series)
(2008)
10.3816/CBC.2002.S.015
Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.
S. Heys (2002)
10.1517/14656566.8.4.485
Docetaxel/anthracycline combinations for breast cancer treatment
G. von Minckwitz (2007)
10.19080/BBOAJ.2017.01.555555
Which is the Preferred Measure of Heterogeneity in Meta-Analysis and Why? A Revisit
S. Dwivedi (2017)
10.1002/14651858.CD201601
'Not knowing' does not necessarily mean there is no plan: redesigning the concept of 'being systematic'
K. Hannes (2016)
10.1016/0277-5379(91)90442-G
Neoadjuvant chemotherapy in operable breast cancer.
S. Scholl (1991)
10.1002/cncr.23544
Taxanes as primary chemotherapy for early breast cancer
F. Cuppone (2008)
systematic review and network meta-analysis [Internet
M Pathak (2018)
10.1002/jrsm.1085
Assessing key assumptions of network meta-analysis: a review of methods.
S. Donegan (2013)
10.1136/bmj.g5630
A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis
M. Puhan (2014)
10.1186/2046-4053-4-1
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
D. Moher (2015)
10.1093/annonc/mds493
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients.
A. Romero (2013)
10.1007/s10549-007-9672-y
A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
K. Lee (2007)
10.1002/ijc.29210
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
J. Ferlay (2015)



This paper is referenced by
10.1155/2020/5209695
Effect of COL4A1 Expression on the Survival of Neoadjuvant Chemotherapy Breast Cancer Patients
Shin-Mae Wang (2020)
10.1245/s10434-020-09252-5
ASO Author Reflections: Modified External Oblique Myocutaneous Flap for Breast Cancer
René Aloisio da Costa Vieira (2020)
10.25122/jml-2019-0115
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
L. Pop (2019)
Convolutional Restricted Boltzmann Machine Based-Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Li Wang (2019)
10.3390/cancers11101528
Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma
Han Ming Poh (2019)
10.1186/s12885-020-06835-z
GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment
A. Raiter (2020)
10.1111/jcmm.14934
Pre‐treatment systemic immune‐inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy
L. Chen (2020)
10.13105/WJMA.V7.I4.170
Effectiveness of taxanes over anthracyclines in neoadjuvant setting: A systematic-review and meta-analysis
M. Pathak (2019)
10.3390/cells9061412
Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems
Maria Grazia Ferraro (2020)
10.1002/jbio.201900216
Evaluation of breast carcinoma regression after preoperative chemotherapy by label-free multiphoton imaging and image analysis.
Lianhuang Li (2019)
10.1016/j.critrevonc.2020.103015
Regimens of neo-adjuvant chemotherapy in the treatment of breast cancer: A systematic review & network meta-analysis with PRISMA-NMA compliance.
M. Pathak (2020)
10.1016/J.CLBC.2019.06.001
Effectiveness of Added Targeted Therapies to Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-analysis.
M. Pathak (2019)
Semantic Scholar Logo Some data provided by SemanticScholar